Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Methotrexate in rheumatoid arthritis: a quarter century of development.

Literature DB >> 23874006

Methotrexate in rheumatoid arthritis: a quarter century of development.

Abstract

Methotrexate (MTX) is now the most popular drug worldwide for the treatment of rheumatoid arthritis. Low-dose, weekly MTX (10 to 25 mg/wk) used as either monotherapy or in combination with other drugs has a superior efficacy profile as defined in placebo-controlled trials and comparable efficacy to other drugs including anti-TNF therapy. At 1 year, one third of patients on MTX have no radiographic progression and even greater effects are seen when combined with targeted biological therapies. MTX is well tolerated; gastrointestinal toxicity is the most common toxicity with rarely bone marrow, lung, or liver toxicity. MTX therapy has been a major advance in the treatment of rheumatoid arthritis and is now the cornerstone of therapy.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23874006 PMCID： PMC3715949

Source DB: PubMed Journal: Trans Am Clin Climatol Assoc ISSN： 0065-7778

33 in total

1. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors: J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245

2. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.

Authors: S FARBER; L K DIAMOND
Journal: N Engl J Med Date: 1948-06-03 Impact factor: 91.245

3. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

Authors: P A Andersen; S G West; J R O'Dell; C S Via; R G Claypool; B L Kotzin
Journal: Ann Intern Med Date: 1985-10 Impact factor: 25.391

4. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.

Authors: H J Williams; R F Willkens; C O Samuelson; G S Alarcón; M Guttadauria; C Yarboro; R P Polisson; S R Weiner; M E Luggen; L M Billingsley
Journal: Arthritis Rheum Date: 1985-07

5. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.

Authors: J M Kremer; J K Lee
Journal: Arthritis Rheum Date: 1986-07

6. Methotrexate therapy in rheumatoid arthritis: 15 years experience.

Authors: R T Hoffmeister
Journal: Am J Med Date: 1983-12-30 Impact factor: 4.965

7. Methotrexate: a perspective of its use in the treatment of rheumatic diseases.

Authors: R F Willkens; M A Watson
Journal: J Lab Clin Med Date: 1982-09

8. Low dose pulse methotrexate therapy in rheumatoid arthritis.

Authors: R F Willkens; M A Watson; C S Paxson
Journal: J Rheumatol Date: 1980 Jul-Aug Impact factor: 4.666

9. Efficacy of low-dose methotrexate in rheumatoid arthritis.

Authors: M E Weinblatt; J S Coblyn; D A Fox; P A Fraser; D E Holdsworth; D N Glass; D E Trentham
Journal: N Engl J Med Date: 1985-03-28 Impact factor: 91.245

10. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis.

Authors: R N Thompson; C Watts; J Edelman; J Esdaile; A S Russell
Journal: J Rheumatol Date: 1984-12 Impact factor: 4.666

58 in total

Review 1. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.

Authors: Bruce N Cronstein; Michail Sitkovsky
Journal: Nat Rev Rheumatol Date: 2016-11-10 Impact factor: 20.543

2. Update on the diagnosis and management of early rheumatoid arthritis.

Authors: Peter C Taylor
Journal: Clin Med (Lond) Date: 2020-11 Impact factor: 2.659

Review 3. Reflections on 'older' drugs: learning new lessons in rheumatology.

Authors: S A Kerrigan; I B McInnes
Journal: Nat Rev Rheumatol Date: 2020-02-17 Impact factor: 20.543

Review 4. In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis-Are We Getting Closer to Personalised Medicine?

Authors: Justyna Roszkiewicz; Elzbieta Smolewska
Journal: Curr Rheumatol Rep Date: 2017-04 Impact factor: 4.592

Review 5. Drugs for discoid lupus erythematosus.

Authors: Sue Jessop; David A Whitelaw; Matthew J Grainge; Prativa Jayasekera
Journal: Cochrane Database Syst Rev Date: 2017-05-05

Review 6. Methotrexate and its mechanisms of action in inflammatory arthritis.

Authors: Bruce N Cronstein; Thomas M Aune
Journal: Nat Rev Rheumatol Date: 2020-02-17 Impact factor: 20.543

Review 7. Efficacy of methotrexate in reducing the risk of bone erosion in patients with rheumatoid arthritis: a systematic review of randomized controlled trials.

Authors: D P Destiani; S Naja; S Dewi; A R Rahmadi; S A S Sulaiman; R Abdulah
Journal: Osteoporos Int Date: 2020-11-18 Impact factor: 4.507

8. Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats.

Authors: Ihab T Abdel-Raheem; Naglaa F Khedr
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2013-12-22 Impact factor: 3.000

Review 9. Intracellular apoptotic pathways: a potential target for reducing joint damage in rheumatoid arthritis.

Authors: Bonnie Williams; Anak Dharmapatni; Tania Crotti
Journal: Inflamm Res Date: 2017-11-21 Impact factor: 4.575

10. Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.

Authors: Anand N Malaviya; S B Gogia
Journal: Clin Rheumatol Date: 2016-04-28 Impact factor: 2.980